The present invention relates to a formulation that can be utilised to facilitate expression of natural behaviour in pigs, and in particular sows and weaners and a method which utilises the formulation for the same.

The present invention relates to a formulation that can be utilised to facilitate expression of natural behaviour in pigs, and in particular sows and weaners and a method which utilises the formulation for the same.

Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

A method for extracting compounds from plant material utilizing terpenes as a solvent is described. The invention includes the excitation of the plant material and terpene solvent with microwave, ultrasound, heat input, and physical agitation or combinations thereof. The invention particularly covers the process as it relates to the extraction of THC and CBD and their derivatives from cannabis and hemp for the use in products for medical and recreational use. The combinations of terpene saturant, plant material strain and process variables can be tuned in order to dial in the final resultant product for several variables including but not limited to terpene content, THC or CBD potency, ratios of THC or CBD and their derivatives, or flavor profile.

This disclosure provides methods and systems for the supercritical fluid extraction of cannabinoids from cannabis. The supercritical fluid extraction of cannabinoids is performed with carbon dioxide (CO.sub.2) balanced with one or more hydrocarbons, such as propane, propene, and propadiene. As demonstrated, the extraction can be carried out at maximum efficiency and energy savings while keeping the wax formation at minimum by lowering temperature. The methods and systems disclosed herein reduce the production time and safety/environmental hazards and are suitable for proper and safe extraction in non-GMP and GMP environments.

The present invention relates, in general terms, to methods of reducing the formation of post-surgery tissue adhesion in a subject in need thereof by administering an adhesion barrier composition. The present invention also relates to methods of preventing the formation of tissue adhesion during or post-surgery in a subject in need thereof. The adhesion barrier composition comprises sporopollenin and a biodegradable polymer. The present invention also relates to methods of fabricating the adhesion barrier composition.

The present invention relates, in general terms, to methods of reducing the formation of post-surgery tissue adhesion in a subject in need thereof by administering an adhesion barrier composition. The present invention also relates to methods of preventing the formation of tissue adhesion during or post-surgery in a subject in need thereof. The adhesion barrier composition comprises sporopollenin and a biodegradable polymer. The present invention also relates to methods of fabricating the adhesion barrier composition.

Disclosed is a powder composition consisting essentially of Magnolia officinalis bark extract comprising magnolol and honokiol, tocopherol or tocopherol acetate, lecithin, at least one gum, and optionally water, wherein the composition is in powdered form.

Disclosed is a powder composition consisting essentially of Magnolia officinalis bark extract comprising magnolol and honokiol, tocopherol or tocopherol acetate, lecithin, at least one gum, and optionally water, wherein the composition is in powdered form.